El guardameta belga se ha instalado en una de las zonas más lujosas de Madrid, en una estructura con una estética moderna, ventanales amplios, geotermia y placas solares... además de vecinos muy famos ...

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Amid mounting concerns about the spread of mpox, an experimental vaccine from Moderna Inc. may be poised to offer additional protection beyond currently available vaccines, research published ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials. “You cannot make a ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed. The companies on Tuesday said the vaccine, in combination ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Un enorme agujero oceánico en Belice acaba de darnos una gran advertencia EEUU se disculpa por deportar a estudiante universitaria que volaba a casa por Acción de Gracias Trump provoca polémica al ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

Two years ago, Triston Casas hit 24 home runs and finished third in American League Rookie of the Year voting, and it looked like the Boston Red Sox had found their first baseman for years to come.

If handcrafted European pastries are your weakness, you’ve been forewarned. Casa Boutique (100 Carondelet Plaza), a new Italian pastry counter, opens December 23 inside Casa Don Alfonso in Clayton.

Dec 18 (Reuters) - Moderna (MRNA.O), opens new tab will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...